Clinical Trials Directory

Trials / Completed

CompletedNCT01488071

A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication

A Randomised, Double-blind, Parallel-group, Active-controlled, Flexible Dose Study Evaluating the Effects of [Vortioxetine] Lu AA21004 Versus Agomelatine in Adult Patients Suffering From Major Depressive Disorder With Inadequate Response to Antidepressant Treatment

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
495 (actual)
Sponsor
H. Lundbeck A/S · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The objective of the present study is to evaluate whether vortioxetine (10 or 20 mg/day) is at least as effective as agomelatine (25 to 50 mg/day) in patients with depressive symptoms that showed inadequate response to Serotonin Reuptake Inhibitors (SRI) antidepressants.

Conditions

Interventions

TypeNameDescription
DRUGVortioxetine (Lu AA21004)encapsulated tablets, daily, orally
DRUGAgomelatineencapsulated tablets, daily, orally

Timeline

Start date
2012-01-01
Primary completion
2012-12-01
First posted
2011-12-08
Last updated
2014-03-26
Results posted
2014-03-26

Source: ClinicalTrials.gov record NCT01488071. Inclusion in this directory is not an endorsement.